Molecular Partners (MOLN) Projected to Post Quarterly Earnings on Monday

Key Points

• Molecular Partners is set to announce its H1 2025 quarterly earnings on August 25th, with analysts predicting a loss of ($0.53) per share.
• In its last earnings report on May 15th, the company reported ($0.50) EPS, missing estimates by ($0.11).
• The company's stock currently trades at $3.54, showing a one-year high of $7.60 and a low of $3.36.

Molecular Partners (NASDAQ:MOLN - Get Free Report) is projected to post its H1 2025 results before the market opens on Monday, August 25th. Analysts expect Molecular Partners to post earnings of ($0.53) per share for the quarter. Individuals can check the company's upcoming H1 2025 earningsummary page for the latest details on the call scheduled for Tuesday, August 26, 2025 at 8:00 AM ET.

Molecular Partners Price Performance

Shares of NASDAQ MOLN traded up $0.21 during midday trading on Friday, reaching $3.76. 2,151 shares of the stock were exchanged, compared to its average volume of 1,058. The business has a 50-day simple moving average of $3.68 and a two-hundred day simple moving average of $4.01. The company has a market capitalization of $151.83 million, a price-to-earnings ratio of -1.96 and a beta of 1.10. Molecular Partners has a 12 month low of $3.36 and a 12 month high of $7.60.

Molecular Partners Company Profile

Molecular Partners AG, a clinical-stage biotechnology company, develops designed ankyrin repeat proteins therapeutics for the treatment of oncology and virology diseases in Switzerland. The company develops MP0317, a CD40 agonist designed to activate immune cells within the tumor microenvironment by anchoring to fibroblast activation protein that is in Phase I clinical trial; and MP0533, a novel tetra-specific T cell-engaging DARPin for acute myeloid leukemia.